Unique ID issued by UMIN | UMIN000003168 |
---|---|
Receipt number | R000003842 |
Scientific Title | Clinical research on concurrent therapy of Ezetimibe and Statin |
Date of disclosure of the study information | 2010/02/12 |
Last modified on | 2010/02/11 13:35:58 |
Clinical research on concurrent therapy of Ezetimibe and Statin
Absorption control Concurrent Therapy study(ACT study)
Clinical research on concurrent therapy of Ezetimibe and Statin
Absorption control Concurrent Therapy study(ACT study)
Japan |
Coronary artery disease or diabetic
Medicine in general | Cardiology | Endocrinology and Metabolism |
Others
NO
Effectiveness and the safety of the concurrent therapy of Ezetimibe and Statin in coronary artery disease and the diabetic.
Safety,Efficacy
Phase IV
Change of LDL-C
1)Accomplishment rate of less than LDL-C100mg/dL and accomplishment rate of less than LDL-C70mg/dL in patient with coronary artery disease.
Or, the accomplishment rate of less than LDL-C value 120mg/dL in the diabetic.
2)Decreasing of hs-CRP.
3)Accomplishment rate of less than LDL-C70mg and less than hs-CRP0.2mg/dL in coronary artery disease person.
4)Change of HDL-C, LDL-C/HDL-C, nonHDL-C.
5)Electrocardiogram(improvement level of ST-T, ventricular rate, left ventricular hypertrophy (SV1+RV5)).
6)Change of kidney function(s-Cr, eGFR).
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Coronary artery disease patients who have more than 100mg/dL of LDL-C in spite of taking statin will be additionally administered ezetimib 10mg/day for 6~9 months.
20 | years-old | <= |
Not applicable |
Male and Female
Coronary artery disease patients who have more than 100mg/dL of LDL-C in spite of taking statin for at least 3 month.
Or, diabetic patients who have more than 120mg/dL of LDL-C in spite of taking statin for at least 3 month.
(1)Patient that there is previous history of hypersensitivity in experimental drug or Statin
(2)TG 400mg/dL or more
(When the measurement of LDL-C is only a calculation method)
(3)Patients with hepatic dysfunction (ALT>3 x upper limit of normal range)
(4)Patients with renal dysfunction (Serum creatinine >2 x upper limit of normal range)
(5)Patient of 9% or more in HbA1c
(6)Patient of 1% or more in change of HbA1c
(7)Patients with secondary hyperlipidemia or medicinal hyperlipemia
(8)Patients with a history of CABG operation or stroke within recent 3 months
(9)Pregnant or possibly pregnant women
(10)Patients who are judged to be inappropriate as a subject by a doctor
200
1st name | |
Middle name | |
Last name | Yoshikazu Hiasa |
Tokushima Red Cross Hospital
Division of cardiology
103 Azairinokuchi,komatsushimacho,Komatsushima,Tokushima
1st name | |
Middle name | |
Last name | TAKAFUMI NAKAGAWA |
Tokushima Red Cross Hospital
Division of cardiology
103 Azairinokuchi,komatsushimacho,Komatsushima,Tokushima
Tokushima Red Cross Hospital
The Kidney Foundation,Japan
Non profit foundation
Japan
NO
2010 | Year | 02 | Month | 12 | Day |
Unpublished
Open public recruiting
2009 | Year | 08 | Month | 05 | Day |
2010 | Year | 02 | Month | 01 | Day |
2010 | Year | 02 | Month | 11 | Day |
2010 | Year | 02 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003842
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |